Persica Pharmaceuticals Strengthens PP353 Rationale in Lumbar Back Pain
LONDON, UK — September 11, 2026 Persica Pharmaceuticals Limited published a new methodological analysis examining the sensitivity of microbiology...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONDON, UK — September 11, 2026 Persica Pharmaceuticals Limited published a new methodological analysis examining the sensitivity of microbiology...
London, UK – July 24, 2026 Persica Pharmaceuticals has presented new scientific analyses supporting the development of its investigational...
